Integrating Engineering, Automation, and Intelligence to Catalyze the Biomedical Translation of Organoids

Ma, Shaohua; Zhao, Haoran; Galan, Edgar A.

doi:10.1002/adbi.202100535

Cited by 6 publications

(3 citation statements)

References 108 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, we can add functional cells at local locations or create a gradient distribution of solution concentrations 4 . In summary, by combining the natural self-organizing properties of organoids with growth regulation, our system will facilitate the development of the next generation of organoids for manufacturing and accelerate progress in disease modeling, organ transplantation, and drug discovery 39 .…”

Section: Discussionmentioning

confidence: 99%

Visual-Servo Micromanipulation Platform for Patterned and Complex Organoid Biofabrication

Gao,

Tong,

HUANG

et al. 2024

Preprint

View full text Add to dashboard Cite

Microwells array-based cellular self-assembly approaches are frequently utilized in organoid manufacturing due to their ability to generate consistent 3D cell spheroids. However, in the context of the microenvironments contained, multiple organ combinations and other complex organoid biofabrication processes are essential, and the lack of controllable inter- and intra-wells heterogeneity has hindered the broader application of these approaches. In this study, we introduce a micromanipulation-based robotic platform that integrates advanced robotic technology and visual-servo systems to enable the patterned and complex organoid biofabrication. By addressing cell seeding-induced fluid perturbations within microwells, we effectively control the spatial distribution of cell, promote self-assembly and achieve precisely arranged of varied types tissue spheroids. This platform supports advancements in complex organoid-based biomechanism discovery, drug screening, and other organoid-based investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

Visual-Servo Micromanipulation Platform for Patterned and Complex Organoid Biofabrication

Gao,

Tong,

HUANG

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…However, the evaluation of vascular integrity and tumor apoptosis has been limited to animal models, which are costly and lack relevance to human biology. Recently, organ- and organoids-on-chips, , have become increasingly popular because of their amenability for automated generation, standardization, and multiplexed analysis in high-throughput. ,,− We chose to develop a vascularized tumor spheroid-on-a-chip model for the performance of these models is comparable with that of animal models, ,, but with the advantages of lower cost, scalability and higher reproducibility. However, we noticed that the models reported in the literature studies used vascular network monolayers; we therefore improved on previous designs by including a thicker (700 μm) vascular bed, which more closely resembles human physiology.…”

Section: Discussionmentioning

confidence: 99%

Vascularized Tumor Spheroid-on-a-Chip Model Verifies Synergistic Vasoprotective and Chemotherapeutic Effects

Cao

Galan

et al. 2022

ACS Biomater. Sci. Eng.

Self Cite

View full text Add to dashboard Cite

Prolyl hydroxylases (PHD) inhibitors have been observed to improve drug distribution in mice tumors via blood vessel normalization, increasing the effectiveness of chemotherapy. These effects are yet to be demonstrated in human cell models. Tumor spheroids are three-dimensional cell clusters that have demonstrated great potential in drug evaluation for personalized medicine. Here, we used a perfusable vascularized tumor spheroid-on-a-chip to simulate the tumor microenvironment in vivo and demonstrated that the PHD inhibitor dimethylallyl glycine prevents the degradation of normal blood vessels while enhancing the efficacy of the anticancer drugs paclitaxel and cisplatin in human esophageal carcinoma (Eca-109) spheroids. Our results point to the potential of this model to evaluate anticancer drugs under more physiologically relevant conditions.

show abstract

“…Although the most of current applications focus on post-experimental data analysis, DL has increasing potential for designing microfluidic systems and controlling systems during experiments 60 . Microfluidics represents an excellent platform for supporting automation and intelligent control of reaction conditions 242 . In the preparation phase of a project, DL can be employed for devices design and materials selection to make OoCs more suitable for specific applications 19 .…”

Section: Integration Ooc Technology With Artificial Intelligencementioning

confidence: 99%

Organ-on-a-chip meets artificial intelligence in drug evaluation

Deng,

Li,

Cao

et al. 2023

Theranostics

View full text Add to dashboard Cite

Drug evaluation has always been an important area of research in the pharmaceutical industry. However, animal welfare protection and other shortcomings of traditional drug development models pose obstacles and challenges to drug evaluation. Organ-on-a-chip (OoC) technology, which simulates human organs on a chip of the physiological environment and functionality, and with high fidelity reproduction organ-level of physiology or pathophysiology, exhibits great promise for innovating the drug development pipeline. Meanwhile, the advancement in artificial intelligence (AI) provides more improvements for the design and data processing of OoCs. Here, we review the current progress that has been made to generate OoC platforms, and how human single and multi-OoCs have been used in applications, including drug testing, disease modeling, and personalized medicine. Moreover, we discuss issues facing the field, such as large data processing and reproducibility, and point to the integration of OoCs and AI in data analysis and automation, which is of great benefit in future drug evaluation. Finally, we look forward to the opportunities and challenges faced by the coupling of OoCs and AI. In summary, advancements in OoCs development, and future combinations with AI, will eventually break the current state of drug evaluation.

show abstract

Integrating Engineering, Automation, and Intelligence to Catalyze the Biomedical Translation of Organoids

Cited by 6 publications

References 108 publications

Visual-Servo Micromanipulation Platform for Patterned and Complex Organoid Biofabrication

Visual-Servo Micromanipulation Platform for Patterned and Complex Organoid Biofabrication

Vascularized Tumor Spheroid-on-a-Chip Model Verifies Synergistic Vasoprotective and Chemotherapeutic Effects

Organ-on-a-chip meets artificial intelligence in drug evaluation

Contact Info

Product

Resources

About